Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed

Boundless Bio, Inc.

2024-Q1 EPS reported -$12.27

Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.
BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.
First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.

Period: the quarter ended March 31, 2024
Net income: $15.4 million
Result: reported results

Exact text from the filing

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Boundless Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.